A new standard of care: Voriconazole

Voriconazole is a crystalline solid, the melting point is 130 ° C.It from 127, and can be used to ergosterol biosynthesis inhibitors as well as antifungal agents.
Voriconazole, has become a new standard of care in the treatment of invasive aspergillosis can occur in immunocompromised patients, including allogeneic BMT, other blood cancers, solid organ transplantation. This is voriconazole .The important thing is based on the results of large randomized trial has proved superior to amphotericin B compared with 32% of amphotericin B, with a partial response or complete 53% , is 71% of patients with voriconazole over amphotericin B provides a survival benefit of 22 percent or more, still alive at 12 weeks in the voriconazole. The longer the duration of treatment significantly fewer severe side effects and the first 13 percent of patients who received initial treatment with voriconazole, amphotericin B, voriconazole also, tolerability was excellent better than amphotericin B compared with 29% of patients who received, was killed in invasive aspergillosis. Design of these studies is called into question, and some consider the (liposomal) amphotericin B as first-line drug yet. Combination therapy with voriconazole and caspofungin against central nervous system aspergillosis site or multiple note is inadequate response or intolerance for must be less considered.With, and other that are Patients with early switch to voriconazole than amphotericin B or lipid formulation that the limited effect of salvage therapy and antifungal agents license, the importance of effective initial treatment has been demonstrated.
Read more:voriconazole online